



**Vaccines and Global Health: The Week in Review**  
**22 February 2025 :: Issue 787**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

*:: [Think Tanks](#)*

*:: [Public Consultations/Call for Inputs/Call for Papers](#)*

## ***Milestones, Perspectives***

.....  
.....

### **"Pandemic Accord"**

#### **Thirteenth meeting of the Intergovernmental Negotiating Body (INB) for a WHO instrument on pandemic prevention, preparedness and response**

**17 – 21 February 2025**

*Webcast recordings*

#### ***Editor's Note:***

We did not identify any summary report on progress or next steps from the session.

.....

#### **WHO Director-General's opening remarks at INB13 – 17 February 2025**

Our Co-Chairs, Precious and Anne-Claire, Our Vice-Chairs, Ambassador Tovar, Ambassador Ramadan, Dr Viroj and Ms Davis,  
Excellencies, dear colleagues and friends, Good morning, and welcome once again to WHO.

Let me begin by thanking the co-chairs, vice-chairs and members of the bureau for your leadership and hard work. Thank you for the text you have proposed, which reflects the different views of Member States, and balances those views with public health needs. And thank you to all Member States for your continuing commitment to this process.

**As you know, we are at a crucial point, as you move to finalize the Pandemic Agreement in time for the World Health Assembly. It really is a case of now or never.** But I am confident that you will choose now, because you know what is at stake.

You remember the hard-won lessons of COVID-19, which left an estimated 20 million of our brothers and sisters dead, and which continues to kill. They are why we are here: to protect future generations from the impact of future pandemics. Because we know that the next pandemic is a matter of when, not if. There are reminders all around us: Ebola, Marburg, measles, mpox, influenza, and the threat of the next disease X.

The catch-cry of the COVID-19 pandemic remains true: no one is safe until everyone is safe. No country can protect itself by itself. Bilateral agreements will only get you so far.

Prevention is the responsibility of all countries; Preparedness is the responsibility of all countries; And response is the responsibility of all countries. Coming together, of course, is not easy; it was never going to be. But that is the power of multilateralism.

**Last Friday, the 14th of February, the Government of the United States of America informed WHO of its decision to withdraw from the intergovernmental process. Like the decision to withdraw from WHO, we regret this decision, and we hope the U.S. will reconsider.**

Thank you all for your hard work and for the great progress you have made, despite the naysayers.

**You have found agreement on so many issues. The finish line is in sight, to build a landmark legal framework, to help the world to prepare, and to prepare well. Together with the important amendments to the International Health Regulations that you adopted last year, the Pandemic Agreement will make us all safer.**

As always, we are grateful for your engagement and guidance, and we look forward to your questions, comments and support. I thank you.

.....  
.....

### **mPox – PHEIC**

*No new digest content identified.*

.....  
.....

### **Polio – PHEIC**

#### **Polio this week – 19 February 2025**

##### ***Headlines***

:: Gaza polio outbreak response continuing – emergency outbreak response in the Gaza Strip is continuing, with a mass vaccination campaign scheduled from 22-26 February, to reach more than 571,000 children. The campaign will aim to address residual immunity gaps, with a subsequent round being planned in April, after Ramadan. Recent detection from environmental samples, including from January, confirms that the strain is still circulating and continues to pose a threat to children with low or no immunity, both in Gaza and throughout the region. [More](#).

:: The recording of the webinar of the recent launch of the updated Global Polio Surveillance Action Plan (GPSAP) is now available online, at this [link](#). The webinar brought together experts from across the GPEI, to summarise the key elements of the GPSAP. The GPSAP maximises benefits of available technical and operational tools and, reflects the key surveillance activities that will facilitate achievement of the GPEI strategic goals to eradicate WPV1 and interrupt transmission of circulating variant poliovirus type 2 (cVDPV2).

##### ***Summary of new polioviruses this week, cases and positive environmental isolates:***

- Afghanistan: One WPV1 case and nine WPV1-positive environmental samples
- Pakistan: Two WPV1 cases and nine WPV1-positive environmental samples
- Algeria: one cVDPV2 case and one cVDPV2-positive environmental sample
- Guinea: one cVDPV3 case
- occupied Palestinian territory: three cVDPV2-positive environmental samples

.....

#### **Mass polio vaccination campaign to continue in the Gaza Strip**

*Joint news note from WHO and UNICEF*

EAST JERUSALEM/AMMAN/GENEVA/NEW YORK, 19 February 2025 - **The emergency polio outbreak response in the Gaza Strip is continuing, with a mass vaccination campaign scheduled from 22 to 26 February 2025.** The novel oral polio vaccine type 2 (nOPV2) will be administered to over 591,000 children under 10 years of age to protect them from polio. This campaign follows the recent detection of poliovirus in wastewater samples in Gaza, signaling ongoing circulation in the environment putting children at risk.

Pockets of individuals with low or no immunity provide the virus an opportunity to continue spreading and potentially cause disease. **The current environment in Gaza, including overcrowding in shelters and severely damaged water, sanitation, and hygiene infrastructure, which facilitates fecal-oral transmission, creates ideal conditions for further spread of poliovirus.** Extensive population movement consequent to the current ceasefire is likely to exacerbate the spread of poliovirus infection.

**Two previous vaccination rounds in the Gaza Strip were successfully conducted in September and October 2024, reaching over 95 per cent of the target.** As poliovirus is found to remain in the environment, additional vaccination efforts are needed to reach every child and strengthen population immunity. The presence of the virus still poses a risk to children with low or no immunity, in Gaza and throughout the region.

In 2024, health workers faced significant challenges accessing certain areas of central, north and south Gaza, which required special coordination to enter during the conflict. In inaccessible areas such as Jabalia, Beit Lahiya, and Beit Hanoun, where humanitarian pauses for the vaccination campaign were not assured, approximately 7 000 children missed vaccination during the second round. The recent ceasefire means health workers have considerably better access now.

No additional polio cases have been reported since a ten-month-old child was paralyzed in August 2024, but the **new environmental samples from Deir al Balah and Khan Younis, collected in December 2024 and January 2025, confirm poliovirus transmission.** The strain detected is genetically linked to the poliovirus detected in the Gaza Strip in July 2024.

**The upcoming vaccination campaign aims to reach all children under 10 years of age, including those previously missed,** to close immunity gaps and end the outbreak. The use of the oral polio vaccine will help end this outbreak by preventing the spread of the virus. **An additional polio vaccination round is planned to be implemented in April.**

**The campaign will be led by the Palestinian Ministry of Health and implemented with support from the World Health Organization (WHO), United Nations Children's Fund (UNICEF), United Nations Relief and Works Agency for Palestine Refugees (UNRWA) and other partners...**

.....  
.....

## **HPAI**

### **[Global Strategy for the Prevention and Control of High Pathogenicity Avian Influenza \(2024–2033\)](#)**

Food and Agriculture Organization of the United Nations and The World Organisation for Animal Health  
19/02/2025 :: 42 pages

PDF: <https://www.woah.org/app/uploads/2025/02/web-gf-tads-hpai-strategy-woah.pdf>

In response to the global ecological and epidemiological changes and repeated intercontinental spread of the H5Nx goose/Guangdong (Gs/GD) lineage high pathogenicity avian influenza (HPAI), the Food and Agriculture Organization of the United Nations (FAO) and the World Organisation for Animal Health (WOAH), under the Global Framework for the Progressive Control of Transboundary Animal Diseases (GF-TADs), have drafted a ten-year global strategy for the prevention and control of high pathogenicity avian influenza (2024–2033).

This replaces the strategy published in 2008 in response to the initial emergence of the H5N1 Gs/GD lineage in Asia. The revised strategy emphasizes a systems approach to contextualize the threat of HPAI against the backdrop of other global concerns. The vision is a world with effective HPAI prevention and control along poultry value chains that supports the protection of domestic animals, wildlife, the environment and humans, and aligns with the Executive summary sustainable transformation of agrifood systems.

### ***Vision statement***

A world with effective HPAI prevention and control along poultry value chains that supports protection of humans, animals and the environment and aligns with the sustainable transformation of poultry and livestock agrifood systems.

### ***Goal***

To substantially and sustainably reduce the impacts of HPAI on poultry, improve the resilience of poultry agrifood systems, safeguard ecosystems, and protect animal and human health.

### **Scope of the global strategy**

This global strategy addresses the prevention, detection and control of HPAI, especially H5 2.3.4.4b and other clades of Gs/GD lineage, that affects poultry, wild birds and other domestic and captive birds and spills over to humans, livestock and wild mammals. Some aspects of the strategy can be used to prevent and control other H5 and H7 HPAI and zoonotic LPAI, such as H9N2, in poultry where measures can significantly reduce the disease burden. Broader application of the strategy can be more limited in wildlife, livestock and human health depending on the avian influenza subtype and pathotype (see Annex 3).

Therefore, the strategy covers the domestic animal health sector component of a wider One Health approach to the prevention and control of HPAI and complements other strategies such as strategies for the human health sector, the WHO Global Influenza Strategy 2019–2030,<sup>14</sup> strategies for the environmental sector including wildlife health, and the July 2023 statement of the Scientific Task Force on Avian Influenza and Wild Birds.<sup>16</sup>

### **PRIMARY TARGET AUDIENCE**


The primary target audience of this strategy includes national veterinary services; wildlife, environment and public health services including laboratories; relevant national One Health partners and sectors; international and regional organizations; economic communities; the private sector; research and educational institutions; and civil society organizations involved in animal health, production and value chains, and zoonotic disease prevention and control.

### **DURATION OF THE STRATEGY**

The strategy covers a 10-year period, i.e. 2024–2033, with a mid-term review to evaluate and update the strategy.

***To officially launch and discuss the new strategy, FAO and WOA will host a technical webinar on March 3, 2025, from 13:00 to 14:30 CET.***

**FIGURE 1.** Global Strategy for the Prevention and Control of High Pathogenicity Avian Influenza (2024–2033): Achieving sustainable, resilient poultry production systems



Source: Adapted from **FAO, WOAH, 2024. Global Strategy for the Prevention and Control of Highly Pathogenic Avian Influenza (2024–2033).** In brief. Rome, FAO.





## Featured Journal Content

### Contemporary Clinical Trials

Volume 149 February 2025

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/149/suppl/C>

*Research article Abstract only*

#### **Advancing vaccine research in Africa: A comprehensive analysis of vaccine clinical trials landscape**

Lindi Mathebula, Thobile Malinga, Chinwe Iwu-Jaja, Duduzile Ndwandwe

Article 107779

#### ***Abstract***

This study presents an in-depth analysis of vaccine clinical trials in Africa, emphasising the significance of local investments to address the continent's healthcare requirements. The research scrutinises vaccine trials across various African nations, focusing on trial distribution, phases, funding sources, recruitment sites, recruitment statuses, and age group participation.

**The findings suggest substantial trial activity in countries like Kenya, Ghana, and Gambia, whereas nations like the Democratic Republic of the Congo and Tunisia exhibit minimal representation. Notably, COVID-19, HIV, and Yellow Fever vaccines prominently feature in the trials, with Phase 3 trials being the most prevalent.** The presence of "Not Applicable" trials indicates adopting adaptive trial designs.

Analysis of funding patterns reveals substantial international and local support, reflecting an escalating commitment to vaccine research in Africa. Nevertheless, concerns persist regarding disparities in trial distribution and age group participation, underscoring the necessity for robust regulatory frameworks and augmented local R&D capacity. Addressing these disparities can enhance the efficacy of vaccine research and elevate health outcomes across the African continent.

#### ***Section snippets***

##### *Background*

Vaccines have been one of the most significant medical advancements in public health, preventing millions of deaths and reducing the incidence of numerous infectious diseases globally. They work by stimulating the immune system to recognise and fight pathogens, such as viruses and bacteria, thereby providing immunity against future infections [1]. Clinical trials are a critical component in the development and approval of vaccines. These trials are conducted in several phases to assess candidate

##### *Aims and objectives*

This study aims to evaluate the landscape of vaccine clinical trials in Africa, focusing on the region's unique challenges and opportunities. **The objectives are to review the current state of vaccine trials over the past two decades, assessing the types of vaccines tested, target diseases, and geographical distribution.** The study will analyse the role of international collaboration and funding in facilitating these trials and evaluating the impact of global health initiatives on local research

##### *Methods*

**We searched the PACTR databases on 15 April 2024 for trials registered since the database's inception in 2009.** Data was downloaded from the database in Microsoft Excel™ for screening and exclusion of non-vaccine trials. We included all vaccine-related trials in our study regardless of the study design or status (i.e., planned, ongoing, or completed). We conducted descriptive analysis in Microsoft Excel™ using tables and bar graphs. All data was stored on the SAMRC network and backed up daily to

Results

The results of this study provide a comprehensive overview of vaccine clinical trials conducted in Africa, highlighting significant findings across various dimensions. **From the 128 registered trials in PACTR as accessed on 15 April 2024, 116 (91 %) were classified as "RCT", 11 (8,6 %) as "CCT" and 1 (0.8 %) "nRCT".** The number of registered trials increased from 1 trial started in 2009 to 28 trials started in 2021. We observed various vaccines tested, targeting diseases such as malaria,

#### *Discussion*

**Our study describes the distribution of vaccine trials registered in the Pan-African Clinical Trials Registry from its inception.** It highlights the major vaccine types, countries where these trials were conducted, the trial phases, and the target pathogens. **Our data suggested a major impact of the COVID-19 pandemic on the number of vaccine trials, with a peak in 2021** followed by a gradual decline, yet maintaining a higher baseline compared to pre-pandemic years. We also compare the number of...

.....  
.....

### **Public Consultations/Call for Inputs/Call for Papers**

#### **E6(R3) Good Clinical Practice: Annex 2; International Council for Harmonisation; Draft Guidance for Industry; Availability**

A Notice by the Food and Drug Administration on 12/30/2024 **Comment period ends 02/28/2025**  
*SUMMARY:*

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "E6(R3) Good Clinical Practice: Annex 2." The draft guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The draft guidance is the second annex to "E6(R3) Good Clinical Practice" published June of 2023. This annex provides additional considerations for the application of good clinical practices to a variety of trial designs and data sources. Specifically, this draft guidance discusses trials with decentralized and pragmatic elements and real-world data sources. This draft guidance highlights the importance of quality by design and focusing efforts and resources on critical aspects of the trials that might impact the safety of participants and the reliability of results. The draft guidance is intended to encourage innovation in trial design and provides flexible, modern, and clear good clinical practices for conducting trials, while avoiding unnecessary complexities.

.....  
.....

#### ***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)

:: [\*WHO\*](#)

:: [\*Organization Announcements\*](#)

:: [\*Journal Watch\*](#)

:: [\*Pre-Print Servers\*](#)

.....  
.....

#### **WHO & Regional Offices [to 22 Feb 2025]**

<https://www.who.int/news>

*Selected News/Announcements/Statements*

*19 February 2025 Joint News Release*

**Mass polio vaccination campaign to continue in the Gaza Strip**



.....

## **WHO Regional Offices**

*Selected Press Releases, Announcements*

### **WHO African Region AFRO**

:: 18 February 2025

[\*\*Uganda discharges all eight Ebola disease patients\*\*](#)

:: 18 February 2025

[\*\*Scaling up mpox outbreak response in Sierra Leone\*\*](#)

:: 17 February 2025

[\*\*Protecting the Central African Republic's remote communities from polio\*\*](#)

:: 14 February 2025

### **WHO Region of the Americas PAHO**

:: 21 Feb 2025

[\*\*PAHO and AECID Strengthen Health Cooperation, Focusing on Cervical Cancer Elimination in the Americas\*\*](#)

Washington, DC, February 21, 2025 (OPS) – The Pan American Health Organization (PAHO) and the Spanish Agency for International Development Cooperation (AECID) have formalized a memorandum of understanding to reinforce their shared commitment to improving public health across the Americas. This agreement marks a decisive step in the fight against...

### **WHO South-East Asia Region SEARO**

*No new digest content identified.*

### **WHO European Region EURO**

:: 17 February 2025 *News release*

[\*\*New WHO/Europe report shows mixed picture in response and recovery during the COVID-19 transition period\*\*](#)

### **WHO Eastern Mediterranean Region EMRO**

:: [\*\*Mass polio vaccination campaign to continue in the Gaza Strip\*\*](#)

19 February 2025

### **WHO Western Pacific Region**

*No new digest content identified.*

.....

## **WHO - Emergency situation reports**

*Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.*

[\*\*Multi-country cholera outbreak, external situation report #23 -20 February 2025\*\*](#)

*Overview*

In January 2025 (epidemiological weeks 1 to 4), a total of 34 799 new cholera and/or Acute Watery Diarrhoea cases were reported from 19 countries, territories, areas across three WHO regions, marking a 27% decrease from December 2024. The African Region registered the highest number of cases, followed by the Eastern Mediterranean Region and the South-East Asia Region. **The period also saw 349 cholera-related deaths globally, highlighting a 33% decrease from the previous month.** While the seasonal decline in transmission during winter months may partly explain the reduction in case numbers in some regions, the overall cholera data remains incomplete due to underreporting and reporting delays.

**In January, Oral Cholera Vaccines production reached 6.2 million doses, reflecting significant efforts by the supplier and partners.** This progress follows the introduction and prequalification of a new vaccine formulation and manufacturing process earlier in 2024. However, **current production has yet to meet growing global demand, and demand continues to exceed supply, hindering efforts to control cholera outbreaks,** respond rapidly to the disease's spread, and implement preventative campaigns.

Conflict, mass displacement, disasters from natural hazards, and climate change have intensified outbreaks, particularly in rural and flood-affected areas, where poor infrastructure and limited healthcare access delay treatment. These cross-border factors have made cholera outbreaks increasingly complex and harder to control.

Cholera upsurge (2021-present): <https://www.who.int/emergencies/situations/cholera-upsurge/>

.....

### **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

#### **[21 February 2025 | Sudan virus disease - Uganda](#)**

*Situation at a glance*

As of 20 February 2025, a total of nine confirmed cases of Sudan virus disease, including one death have been reported from Uganda, since the outbreak was declared on 30 January 2025. Eight cases received care at treatment centres in the capital Kampala and in Mbale and were discharged on 18 February after two negative tests 72 hours apart. As of 20 February 2025, 58 contacts that have been identified are still under follow up in designated quarantine facilities located in Jinja, Kampala, and Mbale. Sudan virus disease belongs to the same family as Ebola virus disease. It is caused by Sudan virus (SUDV). It is a severe disease with high case fatality ranging from 41% to 70% in past outbreaks. In the absence of licensed vaccines and therapeutics for the prevention and treatment of SVD, the risk of potential serious public health impact is high. Early detection, diagnosis, and optimized supportive care may increase the chance of survival.

.....

### **Weekly Epidemiological Record**

<https://www.who.int/publications/journals/weekly-epidemiological-record>

*No new digest content identified.*

.....

### **New WHO Publications**

<https://www.who.int/publications>

*Selected*

21 February 2025

**[Call to action on respiratory pathogen pandemic planning: outcomes from the Global meeting on preparedness and resilience for emerging threats, Geneva, Switzerland, 24-26 April 2023](#)**

21 February 2025 | Technical document

21 February 2025

**[A framework for tracking global progress on preparedness for respiratory pandemics](#)**

*Overview*

A global monitoring framework has been developed to support WHO's Preparedness and Resilience for Emerging Threats (PRET) initiative, focusing on respiratory pathogen pandemic preparedness. This

framework enables WHO, countries, and partners to assess functional capacities for respiratory pandemic preparedness in the areas of emergency coordination, collaborative surveillance, community protection, clinical care, and access to countermeasures. Drawing on insights from the COVID-19 pandemic, the framework provides a structured approach to tracking global progress and identifying areas for improvement to strengthen global resilience against respiratory pathogen threats. Annual progress reports will accompany the framework to showcase the global status of functional capacities needed to prepare for future respiratory pandemics.

19 February 2025

### **Infection prevention and control and water, sanitation and hygiene measures during mpox vaccination activities**

#### *Overview*

This document outlines key infection prevention and control (IPC) principles for safely administering mpox vaccines. Standard precautions should be followed, including ensuring a clean, well-ventilated environment and providing training for health workers and information for the public. Vaccination delivery should align with national IPC guidance, include proper waste management, and avoid unnecessary PPE use.

19 February 2025

### **Technical Science for Health Network: Techne: activity report 2020-2024**

#### *Overview*

The Technical Science for Health Network (WHO-Techne) is a global community of accredited architectural and engineering universities, institutions and associations established by WHO to strengthen emergency preparedness and response operations. To this end, WHO-Techne develops and designs innovative health facility solutions and provides Member States and health partners rapid and customized technical support to realise agreed objectives.

17 February 2025

### **Encephalitis: global threats, trends and public health implications: a technical brief**

.....  
.....

### **USA – HHS, FDA, CDC+**

#### ***Editor's Note:***

*We employ bolded red text below to identify observations we assess might be useful to readers.*

### **HHS**

#### *News*

### **HHS' Civil Rights Office Takes Action to Support President Trump's Executive Orders to Protect Minors and Restore Biological Truth**

February 20, 2025 *News Release*

### **HHS Takes Action on President Trump's Executive Orders Defending Women and Children**

February 19, 2025 *News Release*

### **FDA**

#### *Press Announcements*

*No new digest content identified.*

## **FDA VRBPAC**

*Advisory Committee Calendar*

***The Advisory Committee calendar does not list any future scheduled meetings of any FDA advisory committee, including VRBPAC.***

## **CDC/ACIP [U.S.] [to 22 Feb 2025]**

<http://www.cdc.gov/media/index.html>

*Latest News*

***Last news release 10 Jan 2025.***

## **ACIP Meetings [to 22 Feb 2025]**

*Next ACIP Meeting*

### **ACIP Meeting February 26-28, 2025 Postponed**

The ACIP meeting will be postponed to accommodate public comment in advance of the meeting. The ACIP workgroups met as scheduled this month and will present at the upcoming ACIP meeting.

Agenda for February 26-28

***[Agenda appears stable from earlier agenda versions]***

## **National Vaccine Program**

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

***No 2025 meeting dates posted.***

## **MMWR Weekly**

<https://www.cdc.gov/mmwr/index2024.html>

MMWR Weekly, January 16, 2025 / No. 2

[PDF of this issue](#)

- Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2025
- Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2025

***The January 16th MMWR which we carried in an earlier edition no longer appears on the MMWR webpage.*** We note the two ACIP recommended immunization schedules that comprise this edition. The PDF link below is still active.

.....  
.....

## **Europe**

### **European Medicines Agency [EMA]**

<https://www.ema.europa.eu/en/news>

*News & Press Releases*

*No new digest content identified.*

## **European Centre for Disease Prevention and Control**

<https://www.ecdc.europa.eu/en/News/Updates/Reports/Publications> [Selected]  
*Surveillance and monitoring*

**Communicable disease threats report, 15 - 21 February 2025, week 8**

21 Feb 2025

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 15-21 February and includes updates on cholera, avian influenza A(H9N2) and A(H5N1), chikungunya, Ebola, Legionnaires' disease, dengue, an unknown disease in DRC, and an overview of respiratory virus epidemiology in the EU/EEA.

.....  
.....

**Africa CDC** [to 22 Feb 2025]

<https://africacdc.org/>  
*Press Releases, Statements* [Selected]  
*Press Releases*

**Africa CDC and Global Health EDCTP3 sign Memorandum of Understanding to promote public health in Africa**

17 February 2025

... Building on a previous MoU concluded between the EDCTP Association and Africa CDC in 2021, this new agreement introduces a structured Joint Action Plan (2025-2027) with six key areas of collaboration:

- Strengthening the public health workforce in sub-Saharan Africa, through health research capacity building and training of researchers.
- Strengthening AU member States' clinical trials ecosystems.
- Advancing the clinical development and research on new or improved interventions against infectious diseases prevalent across AU Member States.
- Supporting capacity building activities that are linked to research and innovation, as well as regulatory pathway strengthening, enabling the expansion of local manufacturing of vaccines, diagnostics, and therapeutics in Africa
- Enabling equitable action-oriented partnerships.
- Collaborating on the Pandemic Fund as implementing entities depending on the outcome of the selection process.

.....

**China CDC+**

<http://www.chinacdc.cn/en/>

**National Health Commission of the People's Republic of China** [to 22 Feb 2025]

<http://en.nhc.gov.cn/>  
*News*

**Chinese delegation attends 156th session of WHO Executive Board**

Updated: 2025-02-15

The 156th session of the World Health Organization (WHO) Executive Board was held in Geneva, Switzerland, from Feb 3 to 11. Around 800 representatives from WHO member states, relevant international organizations and non-governmental organizations attended the meeting.

The Chinese delegation comprised representatives from relevant departments of the National Health Commission, the Ministry of Foreign Affairs, the Ministry of Ecology and Environment, the National Administration of Traditional Chinese Medicine, the National Disease Control and Prevention Administration, the National Healthcare Security Administration, and the National Medical Products

Administration, the Permanent Mission of China to the United Nations Office at Geneva as well as relevant experts...

The Chinese delegation played an active part in the discussions on various topics, commended the work done by the WHO, and expressed support for the organization in playing a leading and coordinating role in global health governance. The delegation also shared Chinese experience in relevant fields and called on the WHO to focus on its primary responsibilities and work to further improve efficiency and performance.

They said China is ready to promote cooperation with all parties involved so as to jointly advance the building a global community of health for all.

## **National Medical Products Administration – PRC** [to 22 Feb 2025]

<http://english.nmpa.gov.cn/>

*News*

*No new digest content identified.*

## **China CDC**

### **CCDC Weekly Reports: Current Volume (7)**

2025-02-21 / No. 8 ***HIV ISSUE***

[View PDF of this issue](#)

- Vital Surveillances: The Impact of ART on Stillbirth and Neonatal Death Among HIV-positive Pregnant Women — Yunnan Province, China, 2013–2022
- Preplanned Studies: Risk Assessment of Cardiovascular Disease in HIV Infected Individuals Receiving Antiretroviral Therapy — Shanghai Municipality, China, 2023
- Preplanned Studies: Association Between Incorrect Use of Pre- and Post-Exposure Prophylaxis and HIV infection Among Men Who Have Sex with Men — Shenzhen City, Guangdong Province, China, 2021–2023
- Methods and Applications: Identification of Multiple Unique HIV-1 Recombinant Forms in Newly Reported HIV-1 Infected Individuals — Anhui Province, China, 2023
- Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, January 2025\*

.....  
.....

## ***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)

:: [\*WHO\*](#)

:: [\*Organization Announcements\*](#)

:: [\*Journal Watch\*](#)

:: [\*Pre-Print Servers\*](#)

.....  
.....

## ***Organization Announcements***

## **Paul G. Allen Frontiers Group** [to 22 Feb 2025]

<https://alleninstitute.org/news-press/>

*News*

*No new digest content identified.*

**BMGF - Gates Foundation** [to 22 Feb 2025]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases & Statements*

*No new digest content identified.*

**Bill & Melinda Gates Medical Research Institute** [to 22 Feb 2025]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*News: Articles and Publications*

*No new digest content identified.*

**CARB-X** [to 22 Feb 2025]

<https://carb-x.org/>

*News*

*No new digest content identified.*

**Chan Zuckerberg Initiative** [to 22 Feb 2025]

<https://chanzuckerberg.com/newsroom/>

*Newsroom*

*No new digest content identified.*

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 22 Feb 2025]

<http://cepi.net/>

*CEPI News, Blog*

*Blog*

[Dr Rima Sahay: My Fellowship at CEPI](#)

17 Feb 2025

*Blog*

[Fama Sakho: My Fellowship at CEPI](#)

11 Feb 2025

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 22 Feb 2025]

<https://cioms.ch/>

*News; Publications; Events*

*No new digest content identified.*

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 22 Feb 2025]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*



**DNDI – Drugs for Neglected Diseases initiative** [to 22 Feb 2025]

<https://dndi.org/press/press-releases/>

*Press Releases*

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 22 Feb 2025]

<https://dukeghic.org/>

*News*

*No new digest content identified.*

**EDCTP** [to 22 Feb 2025]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

17 February 2025

[\*\*EMA publishes positive opinion on a fixed-dose combination of albendazole and ivermectin to treat parasitic worm infections\*\*](#)

**Emory Vaccine Center** [to 22 Feb 2025]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 22 Feb 2025]

<http://www.euvaccine.eu/>

*Latest News, Events*

*No new digest content identified.*

**Fondation Merieux** [to 22 Feb 2025]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 22 Feb 2025]

<https://www.gavi.org/>

*Press Releases*

*No new digest content identified.*

**GE2P2 Global Foundation** [to 22 Feb 2025]

[www.ge2p2.org](http://www.ge2p2.org)

*News/Analysis/Publications-Digests/Statements*

- :: [Vaccines and Global Health: The Week in Review](#) - Current edition
- :: [Informed Consent: A Monthly Review – February 2025](#)
- :: [Public Consultations Watch :: Global Calls for Input/Public Comment – 21 Feb 2025](#)

**GHIT Fund** [to 22 Feb 2025]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

*No new digest content identified.*

**Global Fund** [to 22 Feb 2025]

<https://www.theglobalfund.org/en/news/>

*News Releases*

18 February 2025

**[South Africa and the United Kingdom Unite to Co-Host the Eighth Replenishment of the Global Fund, Reinforcing Their Commitment to Global Health](#)**

Under its G20 Presidency, South Africa highlights the urgent need for sustained investment in health systems, vital for the continent and the world's stability, while the UK remains committed to building modern partnerships able to deliver sustainabl...

18 February 2025

**[Global Fund Partnership Launches Investment Case for Eighth Replenishment](#)**

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) today launched the Investment Case for its Eighth Replenishment during a global virtual event emphasizing strong collaboration with global donors and partners in an effort to a...

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 22 Feb 2025]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 22 Feb 2025]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [to 22 Feb 2025]

<https://www.hhmi.org/news>

*Press Room*

*No new digest content identified.*

**Human Immunome Project [nee Human Vaccines Project]** [to 22 Feb 2025]

<https://www.humanimmunomeproject.org/>

*News*

**[Human Immunome Project and Michelson Medical Research Foundation Award \\$150,000 Grants to Three Early-Career Scientists Advancing Immunology and Vaccines](#)**

*Dr. Omar Abudayyeh, Dr. Caleb Lareau, and Dr. Yuzhong Liu, to receive \$150,000 grants for immunology and vaccine research.*

NEW YORK, February 19, 2025 — The Human Immunome Project (HIP) and Michelson Medical Research Foundation (MMRF) have awarded Dr. Omar Abudayyeh (Brigham and Women's Hospital; Harvard Medical School), Dr. Caleb Lareau (Memorial Sloan Kettering Cancer...  
February 19, 2025

**IAVI** [to 22 Feb 2025]

<https://www.iavi.org/>

*Press Releases*

*Features*

**IAVI opens new Vaccine Design and Development Laboratory space in Jersey City, NJ**

February 14, 2025

Leading vaccine research and development lab now housed in an upgraded, fit-for-purpose life sciences facility.

**INSERM** [to 22 Feb 2025]

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use]** [to 22 Feb 2025]

<https://www.ich.org/>

*News/Pubs/Press Releases [Selective]*

*No new digest content identified.*

**ICRC** [to 22 Feb 2025]

<https://www.icrc.org/en/whats-new>

*Latest press releases and statements [Selected]*

*No new digest content identified.*

**IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

**IFRC** [to 22 Feb 2025]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press Releases [Selected]*

## **Türkiye and Syria earthquakes two years on: A long road to recovery**

05/02/2025 | *Press release*

### **IPPS - International Pandemic Preparedness Secretariat** [to 22 Feb 2025]

<https://ippsecretariat.org/news/>

*News*

*No new digest content identified.*

### **Institut Pasteur** [to 22 Feb 2025]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

### **ISC / International Science Council** [to 22 Feb 2025]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*Latest Updates*

#### **Expanded edition of the paper on AI in national research ecosystems focuses on the Global South**

February 17, 2025

The ISC Centre for Science Futures has released the second edition of its working paper — Preparing national research ecosystems for AI — building on the first collection of country case studies. The new edition continues to map the integration of AI into research and science ecosystems, with a particular focus on the Global South.

### **International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News/Events [Selected]*

#### **19th International Congress of Immunology**

Vienna, August 17-22, 2025.

### **IVAC** [to 22 Feb 2025]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

### **IVI** [to 22 Feb 2025]

<http://www.ivi.int/>

*IVI News & Announcements*

#### **International Vaccine Institute Appoints Seth Berkley and Srishti Gupta to Board of Trustees**

February 20, 2025

## **For Africa, in Africa: Leaders Accelerate Action on Vaccine Self-Sufficiency during AU Summit**

February 16, 2025, ADDIS ABABA, Ethiopia – With a strong commitment to vaccine self-sufficiency, African leaders resolve to intensify efforts to enhance vaccine production and access across the continent.

At a key side event at the 38th Ordinary Session of the Assembly of the African Union (AU) in Addis Ababa, **hosted by the Rwandan Ministry of Health, the African Medicines Agency (AMA), and International Vaccine Institute (IVI), policymakers and industry experts convened to advance strategies for sustainable vaccine manufacturing, focusing on continent-wide approaches to regulation, distribution, and equitable access.** The discussion underscored the urgent need to strengthen regulatory frameworks, enhance capacity-building, bolster manufacturing capabilities, and foster partnerships to secure Africa's health future...

### **Johns Hopkins Center for Health Security** [to 22 Feb 2025]

<https://centerforhealthsecurity.org/newsroom>

*Center News [Selected]*

*No new digest content identified.*

### **MSF/Médecins Sans Frontières** [to 22 Feb 2025]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Sudan*

#### **Over 800 people hospitalised and dozens are dead from waterborne infection in Sudan's White Nile state**

Press Release 21 Feb 2025

*Ukraine*

#### **The medical humanitarian needs in Ukraine remain as urgent as ever**

Press Release 21 Feb 2025

### **National Academy of Medicine - USA** [to 22 Feb 2025]

<https://nam.edu/programs/>

*News [Selected]*

*No new digest content identified.*

### **National Academies-Sciences-Engineering-Medicine [NASEM]- USA** [to 22 Feb 2025]

<https://www.nationalacademies.org/newsroom>

*News*

*No new digest content identified.*

### **NIH** [to 22 Feb 2025]

<http://www.nih.gov/>

*News Releases*

*No new digest content identified.*

### **PATH** [to 22 Feb 2025]

<https://www.path.org/media-center/Newsroom>  
*No new digest content identified.*

**Sabin Vaccine Institute** [to 22 Feb 2025]

<https://www.sabin.org/press/>  
*Latest News & Press Releases*  
*No new digest content identified.*

**UNAIDS** [to 22 Feb 2025]

<http://www.unaids.org/en>  
*News, Stories, Updates*  
*Feature story*

### **UNAIDS launches the development of the new Global AIDS Strategy 2026-2031**

20 February 2025

In the past two decades, HIV-related deaths have been reduced by more than half, and millions of people have gained access to life-saving treatment. Scientific breakthroughs, strong political commitment, and community leadership have transformed the HIV response. Yet, despite these remarkable achievements, the path to ending AIDS is still full of challenges.

Today, the HIV response is at a crossroads. Persistent inequalities, financial constraints, and emerging health threats risk derailing progress. The hard-won gains of recent decades must not only be safeguarded but accelerated. This is why UNAIDS is launching the development of the new Global AIDS Strategy 2026-2031, an ambitious, inclusive, and action-driven plan that will guide the global HIV response for the next five years and help end AIDS as a public health threat.

*Feature Story*

### **The critical impact of the PEPFAR funding freeze for HIV across Latin America and the Caribbean**

19 February 2025

The U.S. decision in January to freeze all funding for U.S. foreign assistance, including for the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), has had a critical impact on several countries in Latin America and the Caribbean, exacerbating existing challenges in the HIV response. More than 20 countries in the region rely on these funds to deliver HIV treatment, prevention, and care services, including community-led services focused on the most discriminated and marginalized communities.

**UNICEF** [to 22 Feb 2025]

<https://www.unicef.org/media/press-releases>  
*Latest press releases, news notes and statements*  
*News note 19 February 2025*

### **Mass polio vaccination campaign to continue in the Gaza Strip**

EAST JERUSALEM/AMMAN/GENEVA/NEW YORK, 19 February 2025 - The emergency polio outbreak response in the Gaza Strip is continuing, with a mass vaccination campaign scheduled from 22 to 26 February 2025. The novel oral polio vaccine type 2 (nOPV2) will be administered to over 591,000 children under 10 years of age to ...

*Press release 19 February 2025*

### **Multiple disease outbreaks heighten public health emergencies for children across Eastern and Southern Africa**

NAIROBI, 19 February 2025 - Public health emergencies, including outbreaks of cholera, mpox and, more recently, viral haemorrhagic fevers, are posing significant threats to the safety and wellbeing of millions of children in Eastern and Southern Africa, UNICEF said today...

In 2025, 17 countries in Eastern and Southern Africa are grappling with multiple public health emergencies, the majority of which are outbreaks of vaccine-preventable diseases such as polio, measles and diphtheria. Years of stagnating and declining immunization rates across many countries in the region have resulted in a resurgence of these preventable diseases.

The region is experiencing major outbreaks of viral haemorrhagic fevers, including Marburg virus disease in Tanzania and Ebola disease caused by the Sudan virus in Uganda. Additionally, mpox continues to be a significant health concern, particularly in Burundi and Uganda, with risks of cross-border transmission due to high levels of population movement.

Furthermore, cholera is currently affecting 12 countries, including Angola, Burundi, South Sudan, Zambia, and Zimbabwe, with the region recording the highest number of cholera and acute watery diarrhoea deaths globally.

**Unitaid** [to 22 Feb 2025]

<https://unitaid.org/>

*Featured News*

*No new digest content identified.*

**Vaccine Equity Cooperative [nee Initiative]** [to 22 Feb 2025]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 22 Feb 2025]

<https://www.vaccineacceptance.org/>

*No new digest content identified.*

**Vaccine Confidence Project** [to 22 Feb 2025]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 22 Feb 2025]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

**Wellcome Trust** [to 22 Feb 2025]

<https://wellcome.org/news/all>

*News. Opinion, Reports*

[World Mosquito Program: life-saving innovation in disease control](#)

21 February 2025



**The Wistar Institute** [to 22 Feb 2025]  
<https://www.wistar.org/news/press-releases>  
*Press Releases*  
February 17, 2025

**Scientists at The Wistar Institute's HIV Cure and Viral Diseases Center Develop New Natural Killer Cell Strategy to Target HIV**

PHILADELPHIA — (February 17th, 2025) — Researchers at The Wistar Institute's HIV Cure and Viral Diseases Center have successfully identified a new approach using natural killer (NK) cells to target a...

**World Bank** [to 22 Feb 2025]  
<http://www.worldbank.org/en/news/all>  
*All News [Selected]*  
*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 22 Feb 2025]  
<https://www.wfpha.org/>  
*Blog, Events*

**US withdrawal from WHO**

Feb 20, 2025

The US Withdrawal from WHO: A Threat to Global Health The decision by the US government to sever ties with the World Health Organization (WHO) has far-reaching consequences for public health in the US and globally. The US withdrawal from WHO...

**World Medical Association [WMA]** [to 22 Feb 2025]  
<https://www.wma.net/news-press/press-releases/>  
*Press Releases*  
*No new digest content identified.*

**World Organisation for Animal Health [OIE]** [to 22 Feb 2025]  
<https://www.oie.int/>  
*Press Releases, Statements*  
*News*

**New Global Strategy for the Prevention and Control of High Pathogenicity Avian Influenza**

Published on 21 February 2025

.....  
.....

**ARM [Alliance for Regenerative Medicine]** [to 22 Feb 2025]  
<https://alliancerm.org/press-releases/>  
*Selected Press Releases*  
*No new digest content identified.*

**BIO** [to 22 Feb 2025]  
<https://www.bio.org/press-releases>  
*Press Releases*  
*No new digest announcements identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 22 Feb 2025]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest announcements identified.*

**ICBA – International Council of Biotechnology Associations** [to 22 Feb 2025]

<https://internationalbiotech.org/news/>

*News*

*No new digest announcements identified.*

**IFPMA** [to 22 Feb 2025]

<https://ifpma.org/>

*News, Statements [Selected]*

*Statement 17 February 2025*

**Statement delivered at the 13th Intergovernmental Negotiating Body (INB 13)**

By IFPMA

*On 17 February 2025, IFPMA delivered a statement at the INB 13.*

The biopharmaceutical industry plays a crucial role in pandemic preparedness and response, driving the innovation needed to create pharmaceutical and other relevant products for future health crises.

In strengthening pandemic preparedness and response, there needs to be a clear focus on how to maintain the scientific research on pathogens of pandemic potential, while enhancing equitable access to vaccines and treatments in the event of a pandemic emergency. This can only happen through a robust intellectual property system, which must be safeguarded.

The pharmaceutical industry is committed to expanding access to its products during pandemic emergencies through various means, including donations, equity-based tiered pricing, voluntary licensing, and voluntary technology transfers on mutually agreed terms.

Each pathogen with pandemic potential is unique, and so too will be the response of each company. Different situations and countries may require various interventions at different stages of a pandemic emergency. Therefore, it is crucial to establish a system that is flexible enough to allow a wide variety of companies to leverage their skills and expertise.

To strengthen equitable access, we call on Member States to focus on measures both before and during a pandemic to support healthcare systems, enhance surveillance mechanisms, improve regulatory procedures, develop accurate forecasts, and ensure that companies receive the necessary orders to guide the scale up of production. By overcoming these barriers, Member States can help ensure that life-saving innovations reach those in need. This preparedness and response system must operate effectively at global, regional, and country levels.

We remain dedicated to sharing our experience and providing our expertise to support global health efforts and enhance pandemic preparedness and response.

**International Alliance of Patients' Organizations – IAPO** [to 22 Feb 2025]

<https://www.iapo.org.uk/news>

*Press and media [Selected]*

*No new digest announcements identified.*

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

News

### **IGBA releases first global Intellectual Property and Competition Report (February 2025)**

The International Generic and Biosimilar Medicines Association (IGBA) in line with its goals of promoting the widest possible access to safe, effective, and quality-assured medicines; and of promoting intellectual property regimes which foster innovation and allow the timely entry of generic and biosimilar medicines, has released its report called "GAMING THE SYSTEM- An overview of originator companies' evergreening strategies used to hinder access to generic and biosimilar products".

PDF: [https://www.igbamedicines.org/doc/IGBA\\_IP&Comp\\_Report-v20250123.pdf](https://www.igbamedicines.org/doc/IGBA_IP&Comp_Report-v20250123.pdf)

**PhRMA** [to 22 Feb 2025]

<http://www.phrma.org/>

*Press Releases*

*No new digest announcements identified.*

.....  
.....

### ***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

**AstraZeneca**

*Press Releases* - No new digest content identified.

**Bavarian Nordic**

*Latest News* - No new digest content identified.

**Bharat Biotech**

*Press Releases* - No new digest announcements identified

**BioCubaFarma** – Cuba

*Últimas Noticias* - No new digest announcements identified

**Biological E**

*News* - No new digest announcements identified

**BioNTech**

*Press Releases* - No new digest announcements identified

**Boehringer**

*Press Releases*

### **Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis**

Ingelheim, Germany, Thu, 20/02/2025 - 14:00

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)<sup>[1]</sup> and OXB,<sup>[2]</sup> today announce the start of LENTICLAIR™ 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, gene therapy aiming to improve disease outcomes in people with cystic fibrosis (CF), regardless of gene mutations that are causing the disease. The trial specifically focuses on adults with CF who genetically cannot benefit from cystic fibrosis transmembrane conductance regulator (CFTR) modulators.<sup>[i]</sup>

**CanSinoBIO**

News - Website not responding at inquiry

## **CIGB**

Latest News - No new digest announcements identified.

## **Cinnagen**

Recent News - No new digest announcements identified.

## **Clover Biopharmaceuticals – China**

News - No new digest announcements identified.

## **Curevac**

News

February 18, 2025

[CureVac Earns Repeat Recognition by LexisNexis® as One of the World's Top Innovators](#)

## **Gamaleya National Center/Sputnik**

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

## **GSK**

Press releases for media

21 February 2025

[GSK announces Dr Gavin Screaton to join the Board as Non-Executive Director](#)

## **EuBiologics, S Korea**

News - No new digest announcements identified.

## **IMBCAMS, China**

Home - Website not responding at inquiry.

## **JNJ Innovative Medicine [Janssen]**

Press Releases - No new digest announcements identified.

## **Merck**

News releases - No new digest announcements identified

## **Moderna**

Press Releases - No new digest announcements identified

## **Nanogen**

News - No new digest announcements identified

## **Novartis**

News - No new digest announcements identified.

## **Novavax**

Press Releases - No new digest announcements identified

## **Pfizer**

Recent Press Releases - No new digest announcements identified.

## **R-Pharm**

<https://rpharm-us.com/index.php>

*[No news or media page identified]*

## **Sanofi Pasteur**

[Press Releases](#) - No new digest announcements identified.

## **Serum Institute**

[News & Announcements](#)

### **[European Commission Grants Marketing Authorisation for SIILTIBCY® – A Novel Tuberculosis Skin Test in Europe](#)**

:: SIILTIBCY® is a tuberculosis skin test approved in European Union that detects tuberculosis infection regardless of BCG vaccination status with demonstrated sensitivity and specificity.

:: Full marketing authorisation granted by the European Commission following positive CHMP opinion.

:: The CHMP considered "rdESAT-6 and rCFP-10" as new active substances (NAS).

:: SIILTIBCY® will be launched across EU and EEA member states starting in the first quarter of 2025, with availability varying by country based on local requirements and logistics.

February 18, 2025

## **Sinopharm/WIBPBIBP**

[News](#) - No new digest announcements identified.

## **Sinovac**

[Press Releases](#) - No new digest announcements identified.

## **SK Biosciences**

[Press Releases](#) - No new digest announcements identified.

## **Takeda**

[Newsroom](#) - No new digest announcements identified.

## **Valneva**

[Press Releases](#) - No new digest announcements identified.

## **Vector State Research Centre of Virology and Biotechnology**

[Home](#) - [Website not responding [404 error]]

## **WestVac Biopharma**

[Media](#) - No new digest announcements identified.

## **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[Website](#) [No News/Announcements page identified]

.....  
.....

## ***[Contents](#) [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

### **Journal Watch**

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 16, 2025 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 27, Number 2: E67-166 Feb 2025

<https://journalofethics.ama-assn.org/issue/pain-management-non-labor-and-delivery-obgyn-procedures>

***Issue Theme: Pain Management in Non-Labor and Delivery OBGYN Procedures***

### **American Journal of Human Genetics**

Feb 06, 2025 Volume 112 Issue 2 p199-456

<https://www.cell.com/ajhg/current>

#### **This month in The Journal**

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

Many tools developed for genome-wide analyses perform best in cohorts of a single ancestry group. The genomes of admixed populations contain segments from different ancestry groups and vary from person to person. These features present challenges to investigators who would like to expand the depth, breadth, and diversity of their studies. One approach to control for population structure in admixed populations is local ancestry interference (LAI). By assigning ancestry groups to discrete genomic regions, LAI can boost the power of multiple genomic analyses.

### **American Journal of Infection Control**

February 2025 Volume 53 Issue 2 p175-284

<http://www.ajicjournal.org/current>

[Reviewed earlier]

### **American Journal of Preventive Medicine**

February 2025 Volume 68 Issue 2 p217-428

<https://www.ajpmonline.org/current>

[Reviewed earlier]

## **American Journal of Public Health**

February 2025 115(2)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

## **American Journal of Tropical Medicine and Hygiene**

Volume 112 (2025): Issue 1 (Jan 2025)

<https://www.ajtmh.org/view/journals/tpmd/111/4/tpmd.112.issue-1.xml>

[Reviewed earlier]

## **Annals of Internal Medicine**

February 2025 Volume 178, Issue 2

<https://www.acpjournals.org/toc/aim/current>

*Clinical Guidelines*

### **[Incorporating Economic Evidence in Clinical Guidelines: A Framework From the Clinical Guidelines Committee of the American College of Physicians](#)**

Amir Qaseem, MD, PhD, MHA, Tatyana Shamliyan, MD, MS, Douglas K. Owens, MD, MS, [... et al.](#)

Pages:241–248

*Ideas and Opinions*

### **[The Nuances of Performance Measurement and Clinical Guidelines](#)**

Amir Qaseem, MD, PhD, MHA, Caroline L. Goldzweig, MD, MSHS, Karen Campos, CHES, Brook Watts, MD, [... et al.](#)

Pages:288–289

## **Artificial Intelligence – An International Journal**

Volume 339 February 2025

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/339/suppl/C>

[Reviewed earlier]

## **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 22 Feb 2025)

[No new digest content identified]

## **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 22 Feb 2025)

[No new digest content identified]

## **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 22 Feb 2025)

### **[Measles in Canada: modelling outbreaks with variable vaccine coverage and interventions](#)**



*The global incidence of measles has increased markedly since 2023. In Canada, where measles has had elimination status for more than two decades, most cases can typically be traced to travel. While the majorit...*

Authors: Jennifer McNichol, Javad Valizadeh, Samara Chaudhury and Caroline Colijn

Citation: *BMC Infectious Diseases* 2025 25:236

Content type: Research Published on: 19 February 2025

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 22 Feb 2025)

[No new digest content identified]

### **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 22 Feb 2025)

[No new digest content identified]

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 22 Feb 2025)

[No new digest content identified]

### **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 22 Feb 2025)

#### **[Full vaccination coverage for children aged 12–23 months in Madagascar: Analysis of the 2021 Demographic and Health Survey](#)**

*Vaccination plays a pivotal role in safeguarding the health and wellbeing of children worldwide, preventing the spread of infectious diseases, and reducing mortality rates. Despite significant progress in glob...*

Authors: Florence Gyembuzie Wongnaah, Richard Gyan Aboagye, Augustus Osborne, Abdul-Aziz Seidu and Bright Opoku Ahinkorah

Citation: *BMC Public Health* 2025 25:727

Content type: Research Published on: 21 February 2025

#### **[Drivers of inappropriate use of antibiotics among community members in low- and middle-income countries: a systematic review of qualitative studies](#)**

*The inappropriate use of antibiotics is a major driver of antimicrobial resistance worldwide. Antimicrobial resistance is an alarming public health problem leading to significant morbidity and mortality, parti...*

Authors: Pendo M. Ndaki, Joseph R. Mwanga, Martha F. Mushi, Eveline T. Konje, Stanley M. Mwita and Stephen E. Mshana

Citation: *BMC Public Health* 2025 25:705

Content type: Research Published on: 20 February 2025

#### **[Approaches to engaging faith communities in public health efforts regarding vaccination, genetics, and colorectal cancer: a systematic review](#)**

*Public health professionals regularly engage faith communities to improve public health. This systematic review characterizes approaches that public health professionals have used to engage faith communities a...*

Authors: Ana S. Iltis, Lauren L. Baker, Kari Baldwin, Lucas Cruz, Lauren H. Yaeger and James M. DuBois

Citation: BMC Public Health 2025 25:703

Content type: Systematic Review Published on: 20 February 2025

### **Influence of maternal risk perception and vaccination knowledge on childhood vaccination intentions**

*Vaccine hesitancy remains a significant barrier to effective public health strategies aimed at overcoming the resurgence of vaccine-preventable diseases globally. This study aims to explore the roles of matern...*

Authors: Teh Muthmainnah Md Suhaimi, Aniza Ismail, Rohani Ismail, Nur Syahmina Rasudin, Norhayati Mohd Noor, Ashvini Jayapalan, Zailiza Suli and Mohd Nazir Mohd Nazori

Citation: BMC Public Health 2025 25:671

Content type: Research Published on: 18 February 2025

### **Perceived social support and self-stigma as factors of COVID-19 booster vaccination behavior and intention via cognitive coping and emotion regulation among people infected with COVID-19 in Hong Kong**

*It is imperative to promote behavior/intention of taking up booster COVID-19 vaccination (BI-BV) among people who have ever contracted COVID-19 (PECC). The aims were to investigate the prevalence of BI-BV and ...*

Authors: Xiaoying Zhang, Yiming Luan, Yihan Tang, Mason M. C. Lau, Yanqiu Yu, Jing Gu and Joseph T. F. Lau

Citation: BMC Public Health 2025 25:659

Content type: Research Published on: 18 February 2025

### **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 22 Feb 2025)

[No new digest content identified]

### **BMJ Evidence-Based Medicine**

February 2025 - Volume 30 - 1

<https://ebm.bmj.com/content/30/1>

[Reviewed earlier]

### **BMJ Global Health**

February 2025 - Volume 10 - 2

<https://gh.bmj.com/content/10/2>

[Reviewed earlier]

### **Bulletin of the World Health Organization**

Volume 103, Number 1, January 2025, 1-80

<https://www.who.int/publications/journals/bulletin/>

**In this month's Bulletin**

In the editorial section, Katherine Littler et al. (2) call for papers for a special theme issue on the ethics of research into health and climate change.

Gary Humphreys (5–6) reports on initiatives to mitigate unintended consequences of health policies. Glenda Gray talks to Humphreys (7–8) about her career working on HIV prevention and treatment.  
[Reviewed earlier]

### **Cell**

Feb 06, 2025 Volume 188 Issue 3 p573-868

<https://www.cell.com/cell/current>

[New issue; No digest content identified]

### **Child Care, Health and Development**

Volume 51, Issue 1 January 2025

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

### **Clinical Pharmacology & Therapeutics**

Volume 117, Issue 2 Pages: 311-598 February 2025

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

### **Clinical Therapeutics**

February 2025 Volume 47 Issue 2 p115-178

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

### **Clinical Trials**

Volume 22 Issue 1, February 2025

<https://journals.sagepub.com/toc/ctja/22/1>

[New issue; No digest content identified]

### **Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 22 Feb 2025]

[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 149 February 2025

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/149/suppl/C>

*Research article Abstract only*

**[Advancing vaccine research in Africa: A comprehensive analysis of vaccine clinical trials landscape](#)**

Lindi Mathebula, Thobile Malinga, Chinwe Iwu-Jaja, Duduzile Ndwandwe

Article 107779

*Abstract*

This study presents an in-depth analysis of vaccine clinical trials in Africa, emphasising the significance of local investments to address the continent's healthcare requirements. The research scrutinises vaccine trials across various African nations, focusing on trial distribution, phases, funding sources, recruitment sites, recruitment statuses, and age group participation.

The findings suggest substantial trial activity in countries like Kenya, Ghana, and Gambia, whereas nations like the Democratic Republic of the Congo and Tunisia exhibit minimal representation. Notably, COVID-19, HIV, and Yellow Fever vaccines prominently feature in the trials, with Phase 3 trials being the most prevalent. The presence of "Not Applicable" trials indicates adopting adaptive trial designs.

Analysis of funding patterns reveals substantial international and local support, reflecting an escalating commitment to vaccine research in Africa. Nevertheless, concerns persist regarding disparities in trial distribution and age group participation, underscoring the necessity for robust regulatory frameworks and augmented local R&D capacity. Addressing these disparities can enhance the efficacy of vaccine research and elevate health outcomes across the African continent.

### **The CRISPR Journal**

Volume 8, Issue 1 / February 2025

<https://www.liebertpub.com/toc/crispr/8/1>

Editorial Free

#### **Managing Expectations for CRISPR in a Volatile World**

Rodolphe Barrangou

Published Online: 23 January 2025

<https://doi.org/10.1089/crispr.2025.0006>

### **Current Genetic Medicine Reports**

Volume 11, Issue 3-4 December 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-3>

[Reviewed earlier]

### **Current Medical Research and Opinion**

Volume 41, Issue 1 2025

<https://www.tandfonline.com/toc/icmo20/current>

[New issue; No digest content identified]

### **Current Opinion in Infectious Diseases**

February 2025 - Volume 38 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

### **Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 22 Feb 2025]

[No new digest content identified]

### **Developing World Bioethics**

Volume 24, Issue 4 Pages: 263-342 December 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

### **Development in Practice**

Volume 34, Issue 6, 2024

<https://www.tandfonline.com/toc/cdip20/34/6>

[Reviewed earlier]

### **Development Policy Review**

Volume 43, Issue 2 March 2025

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 19 - 2025

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[New issue; No digest content identified]

### **Disasters**

Volume 49, Issue 1 January 2025

<https://onlinelibrary.wiley.com/toc/14677717/2025/49/1>

[Reviewed earlier]

### **EMBO Reports**

Volume 26 Issue 3 10 February 2025

<https://www.embopress.org/toc/14693178/current>

*Science & Society* 20 January 2025

**[The controls that got out of control: How failed control experiments paved the way to transformative discoveries](#)**

André Schneider

When experimental controls go wrong, it does not necessarily mean your experiment is flawed. It might well be the first sign of something unexpected.

### **Emerging Infectious Diseases**

Volume 31, Number 2—February 2025

<http://wwwnc.cdc.gov/eid/>

*Research*

**[Epidemiologic and Genomic Surveillance of \*Vibrio cholerae\* and Effectiveness of Single-Dose Oral Cholera Vaccine, Democratic Republic of the Congo \[PDF - 1.98 MB - 10 pages\]](#)**

C. George et al.

**[Global Epidemiology of Outbreaks of Unknown Cause Identified by Open-Source Intelligence, 2020–2022 \[PDF - 1.84 MB - 11 pages\]](#)**

D. Honeyman et al

## **Epidemics**

Volume 49 December 2024

<https://www.sciencedirect.com/journal/epidemics/vol/49/suppl/C>

[Reviewed earlier]

## **Epidemiology and Infection**

Volume 153 - 2025

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

## **Ethics & Human Research**

Volume 47, Issue 1 Pages: 1-45 January–February 2025

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Moral distress in clinical research • Research with incarcerated and homeless women***

[Reviewed earlier]

## **Ethics & International Affairs**

Volume 38 - Issue 3 - Fall 2024

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

## **Ethics, Medicine and Public Health**

Volume 32 2024

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>

[Reviewed earlier]

## **The European Journal of Public Health**

Volume 35, Issue 1, February 2025

<https://academic.oup.com/eurpub/issue/35/1>

*COVID-19*

**[Lessons learned from Taiwan's response to the COVID-19 pandemic: successes, challenges, and implications for future pandemics](#)**

Vivian Chia-Rong Hsieh and others

European Journal of Public Health, Volume 35, Issue 1, February 2025, Pages 153–162,

<https://doi.org/10.1093/eurpub/ckae185>

## **Expert Review of Vaccines**

Volume 24, 2025 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

## **Foreign Affairs**

January/February 2025

<https://www.foreignaffairs.com/issues/2025/104/1>

*Special Section*

## ***Will Trump Change the World?***

### **Forum for Development Studies**

Volume 51, 2024 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

### **Frontiers in Medicine**

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1237>

[Accessed 22 Feb 2025]

[No new digest content identified]

### **Gene Therapy – Nature**

Volume 32 Issue 1, January 2025

<https://www.nature.com/gt/volumes/32/issues/1>

[Reviewed earlier]

### **Genetics in Medicines**

Volume 27, Issue 2 February 2025

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/2>

[Reviewed earlier]

### **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 22 Feb 2025]

[No new digest content identified]

### **Global Health Action**

Volume 18, Issue 1 (2025)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[New issue; No digest content identified]

### **Global Health: Science and Practice (GHSP)**

Vol. 12, No. 6 December 20, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

### **Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc)

[Accessed 22 Feb 2025]

[No new digest content identified]



### **Global Public Health**

Volume 20, Issue 1 (2025)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 22 Feb 2025]

[No new digest content identified]

### **Health and Human Rights**

Volume 26, Issue 2, December 2024

<https://www.hhrjournal.org/volume-26-issue-2-december-2024/>

***Special Section: Distress Migration and the Right to Health***

[Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 19 - Issue 4 - October 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

### **Health Policy and Planning**

Volume 40, Issue 2, March 2025

<https://academic.oup.com/heapol/issue/40/2>

[New issue; No digest content identified]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 22 Feb 2025]

[No new digest content identified]

### **Human Gene Therapy**

Volume 36, Issue 3-4 / February 2025

<https://www.liebertpub.com/toc/hum/36/3-4>

[Reviewed earlier]

### **Humanitarian Practice Network**

<https://odihpn.org/>

*Featured Publications*

[No new digest content identified]

### **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 20 Issue 1, 2024

<https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList>  
*Selected Content*  
[Reviewed earlier]

### **Immunity**

Feb 11, 2025 Volume 58 Issue 2 p265-514  
<https://www.cell.com/immunity/current>  
[Reviewed earlier]

### **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>  
[Accessed 22 Feb 2025]  
[No new digest content identified]

### **Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>  
[Accessed 22 Feb 2025]  
[No new digest content identified]

### **International Health**

Volume 17, Issue 1, January 2025  
<https://academic.oup.com/inthealth/issue/17/1>  
[Reviewed earlier]

### **International Human Rights Law Review**

Volume 13 (2024): Issue 2 (Dec 2024)  
<https://brill.com/view/journals/hrlr/13/2/hrlr.13.issue-2.xml>  
[Reviewed earlier]

### **International Journal of Community Medicine and Public Health**

Vol. 12 No. 2 (2025): February 2025  
<https://www.ijcmph.com/index.php/ijcmph/issue/view/121>

#### *Articles*

#### **[Predictors of knowledge, attitude and perception of diphtheria infection and vaccination among medical students in Abubakar Tafawa Balewa University, Bauchi North-Eastern Nigeria](#)**

Abubakar Musa, Usman Abba, Esther Adesina Oluwatobi, Aishat Haruna Ojochenemi, Abel Acheneje Abutu, Muhammad Bashir Jibril, Mohammed Kabir Abdullahi  
709-718  
DOI: [10.18203/2394-6040.ijcmph20250301](https://doi.org/10.18203/2394-6040.ijcmph20250301)

#### **[Assessing the effectiveness of vaccination strategies against respiratory pathogens](#)**

Marwah Y. Abdullah, Faisal M. Alanazi, Saad F. Gandurah, Dhiyaa A. Altufayif, Abdulrahman M. Alghamdi, Olfa A. Halawani, Fatimah F. Almudarhem, Raghad I. Al-Otaibe, Osama M. Allathiqani, Amani A. Alasmari  
967-973

DOI: [10.18203/2394-6040.ijcmph20250065](https://doi.org/10.18203/2394-6040.ijcmph20250065)

**[A comprehensive review of the latest Indian guidelines on adult immunization](#)**

Aditi M. Dhawan, Anish Desai, Aanchal Gvalani, Sunaina Anand, Priyanka Das  
1159-1165

DOI: [10.18203/2394-6040.ijcmph20250339](https://doi.org/10.18203/2394-6040.ijcmph20250339)

**International Journal of Epidemiology**

Volume 53, Issue 6, December 2024

<https://academic.oup.com/ije/issue/53/6>

[Reviewed earlier]

**International Journal of Human Rights in Healthcare**

Volume 17 Issue 4 2024

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/4>

*Table of contents*

[Reviewed earlier]

**JAMA**

February 18, 2025, Vol 333, No. 7, Pages 551-644

<https://jamanetwork.com/journals/jama/currentissue>

[New issue; No digest content identified]

**JAMA Health Forum**

January 2025, Vol 6, No. 1

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

**JAMA Pediatrics**

February 2025, Vol 179, No. 2, Pages 111-224

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[New issue; No digest content identified]

**JBİ Evidence Synthesis**

February 2025 - Volume 23 - Issue 2

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

*Evidence Syntheses*

**[Parental experiences of caring for their preschool children after declining vaccines: a qualitative systematic review](#)**

Huel, Christine; MacKinnon, Karen; Harding, Jillian; More  
JBİ Evidence Synthesis. 23(2):244-332, February 2025.

**Journal of Adolescent Health**

March 2025 Volume 76 Issue 3 p341-526

<https://www.jahonline.org/current>

[Reviewed earlier]

### **Journal of Artificial Intelligence Research**

Vol. 82 (2025)

<https://www.jair.org/index.php/jair>

*Contents*

[New issue; No digest content identified]

### **Journal of Community Health**

Volume 50, Issue 1 February 2025

<https://link.springer.com/journal/10900/volumes-and-issues/50-1>

*Articles*

#### **Messaging Preferences about the COVID-19 Vaccine among Adults in Eastern North Carolina**

Abby J. Schwartz, Alice R. Richman, Essie Torres

Original paper Open access 05 September 2024 Pages: 71 - 80

#### **Evaluation of Human Papillomavirus Vaccination and Cancer Prevention Behaviors among LGBTQI + Individuals: A Cross-Sectional Study**

Sanjana K. Rana, Rebecca B. Perkins, Alessandro Villa

Original Paper 05 September 2024 Pages: 98 - 110

### **Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

Vol. 8 No. 01 (2025)

<https://www.cmro.in/index.php/jcmro/issue/view/91>

[Reviewed earlier]

### **Journal of Development Economics**

Volume 173 March 2025

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/173/suppl/C>

[New issue; No digest content identified]

### **Journal of Empirical Research on Human Research Ethics**

Volume 19 Issue 4-5, October–December 2024

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

### **Journal of Epidemiology & Community Health**

March 2025 - Volume 79 - 3

<https://jech.bmj.com/content/79/3>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 18, Issue 1 March 2025

<https://onlinelibrary.wiley.com/toc/17565391/current>

[New issue; No digest content identified]

**Journal of Global Ethics**

Volume 20, Issue 3 (2024)

<http://www.tandfonline.com/toc/rjge20/current>

***Special Issue: 20th Anniversary Forum***

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 36, Number 1, February 2025

<https://muse.jhu.edu/issue/54278>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 27, Issue 1 February 2025

<https://link.springer.com/journal/10903/volumes-and-issues/27-1>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 23, Issue 1 (2025)

<https://www.tandfonline.com/toc/wimm20/current>

[New issue; No digest content identified]

**Journal of International Development**

Volume 37, Issue 1 Pages: 1-349 January 2025

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

**Journal of Medical Ethics**

February 2025 - Volume 51 - 2

<http://jme.bmj.com/content/current>

[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 11, Issue 3 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

**The Journal of Pediatrics**

Volume 277 February 2025

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/277/suppl/C>  
[New issue; No digest content identified]

**Journal of Pharmaceutical Policy and Practice**

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

**Journal of Public Health Management & Practice**

January/February 2025 - Volume 31 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Public Health Policy**

Volume 45, issue 4, December 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-4>

[Reviewed earlier]

**Journal of the Royal Society – Interface**

February 2025 Volume 22 Issue 223

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

**Journal of Travel Medicine**

Volume 32, Issue 1, January 2025

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

**Journal of Virology**

Volume 98 Number 12 December 2024

<http://jvi.asm.org/content/current>

[Reviewed earlier]

**The Lancet**

Feb 22, 2025 Volume 405 Number 10479 p597-670

<https://www.thelancet.com/journals/lancet/issue/current>

[New issue; No digest content identified]

**The Lancet Child & Adolescent Health**

Feb 2025 Volume 9 Number 2 p77-150, e1-e3

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

### **Lancet Digital Health**

Feb 2025 Volume 7 Number 2 e103-e166

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

### **Lancet Global Health**

Feb 2025 Volume 13 Number 2 e172-e371

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

### **Lancet Infectious Diseases**

Feb 2025 Volume 25 Number 2 p135-242, e60-e113

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

### **Lancet Public Health**

Feb 2025 Volume 10 Number 2 e71-e164

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

### **Lancet Respiratory Medicine**

Feb 2025 Volume 13 Number 2 p101-188, e9-e16

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

### **Maternal and Child Health Journal**

Volume 29, Issue 2 February 2025

<https://link.springer.com/journal/10995/volumes-and-issues/29-2>

[New issue; No digest content identified]

### **Medical Decision Making (MDM)**

Volume 45 Issue 2, February 2025

<http://mdm.sagepub.com/content/current>

*Research article Open access*

First published online December 24, 2024

[\*\*Testing an HPV Vaccine Decision Aid for 27- to 45-Year-Old Adults in the United States: A Randomized Trial\*\*](#)

[Erika L. Thompson](#)

### **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 102, Issue 4 Pages: 823-1031 December 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

## **Molecular Therapy**

Feb 05, 2025 Volume 33 Issue 2 p423-824

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

## **Nature**

Volume 638 Issue 8051, 20 February 2025

<https://www.nature.com/nature/volumes/638/issues/8051>

Perspective 19 Feb 2025

### **[Artificial intelligence for modelling infectious disease epidemics](#)**

*This Perspective considers the application to infectious disease modelling of AI systems that combine machine learning, computational statistics, information retrieval and data science.*

Moritz U. G. Kraemer, Joseph L.-H. Tsui, Samir Bhatt

#### ***Abstract***

Infectious disease threats to individual and public health are numerous, varied and frequently unexpected. Artificial intelligence (AI) and related technologies, which are already supporting human decision making in economics, medicine and social science, have the potential to transform the scope and power of infectious disease epidemiology. Here we consider the application to infectious disease modelling of AI systems that combine machine learning, computational statistics, information retrieval and data science. We first outline how recent advances in AI can accelerate breakthroughs in answering key epidemiological questions and we discuss specific AI methods that can be applied to routinely collected infectious disease surveillance data. Second, we elaborate on the social context of AI for infectious disease epidemiology, including issues such as explainability, safety, accountability and ethics. Finally, we summarize some limitations of AI applications in this field and provide recommendations for how infectious disease epidemiology can harness most effectively current and future developments in AI.

## **Nature Biotechnology**

Volume 43 Issue 2, February 2025

<https://www.nature.com/nbt/volumes/43/issues/2>

[Reviewed earlier]

## **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 22 Feb 2025)

[Reviewed earlier]

## **Nature Genetics**

Volume 57 Issue 2, February 2025

<https://www.nature.com/ng/volumes/57/issues/2>

[Reviewed earlier]

## **Nature Human Behaviour**

Volume 9 Issue 1, January 2025

<https://www.nature.com/nathumbehav/volumes/9/issues/1>

[Reviewed earlier]



## **Nature Medicine**

Volume 31 Issue 2, February 2025

<https://www.nature.com/nm/volumes/31/issues/2>

*Review Article* 03 Feb 2025

### **Clinical applications of human organoids**

Organoid research is moving beyond developmental and disease biology, driving insights into current and emerging health threats and enabling personalized and regenerative medicine applications.

Monique M. A. Verstegen, Rob P. Coppes, Luc J. W. van der Laan

#### *Abstract*

Organoids are innovative three-dimensional and self-organizing cell cultures of various lineages that can be used to study diverse tissues and organs. Human organoids have dramatically increased our understanding of developmental and disease biology. They provide a patient-specific model to study known diseases, with advantages over animal models, and can also provide insights into emerging and future health threats related to climate change, zoonotic infections, environmental pollutants or even microgravity during space exploration. Furthermore, organoids show potential for regenerative cell therapies and organ transplantation. Still, several challenges for broad clinical application remain, including inefficiencies in initiation and expansion, increasing model complexity and difficulties with upscaling clinical-grade cultures and developing more organ-specific human tissue microenvironments. To achieve the full potential of organoid technology, interdisciplinary efforts are needed, integrating advances from biology, bioengineering, computational science, ethics and clinical research. In this Review, we showcase pivotal achievements in epithelial organoid research and technologies and provide an outlook for the future of organoids in advancing human health and medicine.

## **Nature Reviews Drug Discovery**

Volume 24 Issue 1, January 2025

<https://www.nature.com/nrd/volumes/24/issues/1>

[Reviewed earlier]

## **Nature Reviews Genetics**

Volume 26 Issue 2, February 2025

<https://www.nature.com/nrg/volumes/26/issues/2>

[Reviewed earlier]

## **Nature Reviews Immunology**

Volume 25 Issue 1, January 2025

<https://www.nature.com/nri/volumes/25/issues/1>

[Reviewed earlier]

## **New England Journal of Medicine**

Volume 392 No. 8 February 20, 2025

<https://www.nejm.org/toc/nejm/medical-journal>

*Original Articles*

### **Low-Dose Yellow Fever Vaccine in Adults in Africa**

D. Kimathi and Others

A yellow fever vaccination dose as low as 500 IU was noninferior to the standard dose of 13,803 IU for producing seroconversion within 28 days. (Funded by the European and Developing Countries Clinical Trials Partnership and the Wellcome Trust; NIFTY ClinicalTrials.gov number, [NCT04059471](#).)

### **NEJM Evidence**

Volume 4 No. 2 February 2025

<https://evidence.nejm.org/toc/evid/current>

*NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.*

[Reviewed earlier]

### **njp Vaccines**

<https://www.nature.com/njpvaccines/>

[Accessed 22 Feb 2025]

*Perspective* 19 Feb 2025

[\*\*Product and trial design considerations on the path towards a vaccine to combat opioid overdose\*\*](#)

Asimenia Angelidou, Jacob A. Koster, Ofer Levy

### **Pediatrics**

Volume 155, Issue 2 February 2025

<https://publications.aap.org/pediatrics/issue/155/2>

[Reviewed earlier]

### **PharmacoEconomics**

Volume 43, Issue 3 March 2025

<https://link.springer.com/journal/40273/volumes-and-issues/43-3>

[Reviewed earlier]

### **PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 22 Feb 2025)

[No new digest content identified]

### **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 22 Feb 2025)

[No new digest content identified]

### **PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSglobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSglobalPublicHealth&q=&resultsPerPage=60)

(Accessed 22 Feb 2025)

[\*\*Perceptions and predictors of COVID-19 vaccine hesitancy among healthcare providers across five countries in sub-Saharan Africa\*\*](#)

Isabel Madzorera, Livesy Naafoe Abokyi, Edward Apraku, Temesgen Azemraw, Valentin Boudo, Christabel James, Dongqing Wang, Frank Mapendo, Ourohiré Millogo, Nega Assefa, Angela Chukwu, Firehiwot Workneh, Bruno Lankoande, Elena C. Hemler, Abbas Ismail, Sulemana Abubakari, Kwaku Poku Asante, Yemane Berhane, Japhet Killewo, Ayoade Oduola, Ali Sie, Abdramane Soura, Mary Mwanyika-Sando, Said Vuai, Emily Smith, Till Baernighausen, Raji Tajudeen, Wafaie W. Fawzi  
Research Article | published 21 Feb 2025 PLOS Global Public Health  
<https://doi.org/10.1371/journal.pgph.0003956>

**Trends and determinants of complete vaccination coverage among children aged 12–59 months: An analysis of Bénin Demographic and Health Surveys from 1996 to 2018**

Jean-Pierre Gnimatin, Shiméa M. Agossou, Lauryn L. A. Hinde, Joyce Aputere Ndagou, Emmanuel Owusu Dankwah, Joël Segnon, Quynh Ngoc Thuy Ho, Martin Nyaaba Adokiya  
Research Article | published 20 Feb 2025 PLOS Global Public Health  
<https://doi.org/10.1371/journal.pgph.0004206>

**Global and national actions to prevent trade in substandard and adulterated medicines**

Richard Wilder, Sam Halabi, Lawrence O. Gostin  
Essay | published 20 Feb 2025 PLOS Global Public Health  
<https://doi.org/10.1371/journal.pgph.0004024>

**PLoS Medicine**

<https://journals.plos.org/plosmedicine/>  
(Accessed 22 Feb 2025)  
[No new digest content identified]

**PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>  
(Accessed 22 Feb 2025)

**Revisiting What Constitutes a Neglected Tropical Disease?**

Paul J. Brindley, Peter J. Hotez, Shaden Kamhawi  
Editorial | published 20 Feb 2025 PLOS Neglected Tropical Diseases  
<https://doi.org/10.1371/journal.pntd.0012794>

**Impact of a multi-pronged cholera intervention in an endemic setting**

Alexandre Blake, Adam Walder, Ephraim M. Hanks, Placide Okitayemba Welo, Francisco Luquero, Didier Bompangue, Nita Bharti  
Research Article | published 19 Feb 2025 PLOS Neglected Tropical Diseases  
<https://doi.org/10.1371/journal.pntd.0012867>

**PLoS One**

<http://www.plosone.org/>  
[Accessed 22 Feb 2025]

**Multi-level quality assessment of United States COVID-19 epidemiological surveillance**

Megan S. Irgens, Riley M. O'Neill, John M. Ruiz  
Research Article | published 21 Feb 2025 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0319263>

**PLoS Pathogens**

<http://journals.plos.org/plospathogens/>  
[Accessed 22 Feb 2025]  
[No new digest content identified]

### **PNAS - Proceedings of the National Academy of Sciences of the United States**

February 25, 2025 | vol. 122 | no. 8  
<https://www.pnas.org/toc/pnas/122/8>  
[New issue; No digest content identified]

### **PNAS Nexus**

Volume 4, Issue 1, January 2025  
<https://academic.oup.com/pnasnexus/issue/4/1>  
[Reviewed earlier]

### **Prehospital & Disaster Medicine**

Volume 39 - Issue 6 - December 2024  
<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>  
[Reviewed earlier]

### **Preventive Medicine**

Volume 191 February 2025  
<https://www.sciencedirect.com/journal/preventive-medicine/vol/191/suppl/C>  
[Reviewed earlier]

### **Proceedings of the Royal Society B**

February 2025 Volume 292 Issue 2040  
<https://royalsocietypublishing.org/toc/rspb/current>  
[Reviewed earlier]

### **Public Health**

Volume 239 Pages 1-242 (February 2025)  
<https://www.sciencedirect.com/journal/public-health/vol/239/suppl/C>  
*Research article Abstract only*

#### **[The burden of dengue in South American countries, 1990–2019: Estimates from the Global Burden of Disease study 2019](#)**

C.S. Navarro, P.A.S. Vaz de Castro, G.R. de Araújo, I.R. Ávila, ... J.M.T. Bezerra  
Pages 121-126

### **Public Health Ethics**

Volume 17, Issue 3, November 2024  
<http://phe.oxfordjournals.org/content/current>  
[Reviewed earlier]

### **Public Health Genomics**

2025, Vol. 28, No. 1  
<https://karger.com/phg/issue/28/1>  
[Reviewed earlier]

### **Public Health Reports**

Volume 140 Issue 1, January/February 2025  
<https://journals.sagepub.com/toc/phrg/140/1>  
[Reviewed earlier]

### **Qualitative Health Research**

Volume 35 Issue 2, February 2025  
<https://journals.sagepub.com/toc/QHR/current>  
[Reviewed earlier]

### **Research Ethics**

Volume 21 Issue 1, January 2025  
<http://journals.sagepub.com/toc/reab/current>  
[Reviewed earlier]

### **Reproductive Health**

<http://www.reproductive-health-journal.com/content>  
[Accessed 22 Feb 2025]  
[No new digest content identified]

### **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Latest Articles*

21 Feb 2025

[\*\*The role of the Pan American Committee for Safe Vaccination \(COPAVASE\) in strengthening safe vaccination in the Americas\*\*](#)

Special report | Spanish |

21 Feb 2025

[\*\*Oropouche virus – another antecedent event for Guillain–Barré syndrome?\*\*](#)

Current topic | English |

20 Feb 2025

[\*\*From hope to reality: How telehealth and strategic procurement are reshaping public health\*\*](#)

Editorial | English |

### **Risk Analysis**

Volume 45, Issue 2 pages: 265-472 February 2025  
<https://onlinelibrary.wiley.com/toc/15396924/current>  
[Reviewed earlier]

## **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 22 Feb 2025]

[No new digest content identified]

## **Royal Society Open Science**

February 2025 Volume 12 Issue 2

<https://royalsocietypublishing.org/toc/rsos/current>

[Reviewed earlier]

## **Science**

Volume 387| Issue 6736| 21 Feb 2025

<https://www.science.org/toc/science/current>

*Editorial*

### **[A direct hit](#)**

BY H. Holden Thorp

11 Feb 2025

*[Excerpt]*

Earlier this month, the Trump administration set off a frenzy in the US scientific community when the National Institutes of Health (NIH) announced that indirect cost reimbursement for federally funded research would be capped at 15%, a drastic cut from a usual range of 50 to 70%. In the American system, a federal research grant comes with one component that pays the direct costs of research—covering salaries of the researchers and supplies and equipment they use—and a so-called indirect component that represents the government’s contribution to facilities and administration—the overhead necessary to do the work. The indirect contribution does not cover everything needed to support the research; the remainder is provided by the university. This agreement between higher education and the government has been a hallmark of the funding system for 70 years. The scientific community must unite in speaking out against this betrayal of a partnership that has enabled American innovation and progress...

These cuts should be a rallying cry for higher education to come together to make the case for the American system of research and teaching. Leaders have an opportunity to step forward and marshal their campuses in the effort. Conflicts between faculty and administrators, no matter how justifiable, should be set aside to focus attention on this ruthless takedown of academia. All disciplines will be affected by these cuts, not just science. This is a moment to unite.

*Research Articles*

### **[Simulating 500 million years of evolution with a language model](#)**

BY Thomas Hayes, et al.

16 Jan 2025

## **Science and Engineering Ethics**

Volume 31, Issue 1 February 2025

<https://link.springer.com/journal/11948/volumes-and-issues/31-1>

[Reviewed earlier]

## **Science Translational Medicine**

Volume 17| Issue 786| 19 Feb 2025  
<https://www.science.org/toc/stm/current>  
[New issue; No digest content identified]

### **Scientific Reports**

<https://www.nature.com/srep/articles?type=article>  
[Accessed 22 Feb 2025]  
[No new digest content identified]

### **Social Science & Medicine**

Volume 364 January 2025  
<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/364/suppl/C>  
[Reviewed earlier]

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>  
[Accessed 22 Feb 2025]  
[No new digest content identified]

### **Theoretical Medicine and Bioethics**

Volume 45, Issue 6 December 2024  
<https://link.springer.com/journal/11017/volumes-and-issues/45-6>  
[Reviewed earlier]

### **Travel Medicine and Infectious Diseases**

Volume 63 January–February 2025  
<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/63/suppl/C>  
[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 30, Issue 2 Pages: i-iv, 71-142 February 2025  
<https://onlinelibrary.wiley.com/toc/13653156/current>  
[Reviewed earlier]

### **Vaccine**

Volume 48 27 February 2025  
<https://www.sciencedirect.com/journal/vaccine/vol/48/suppl/C>

*Discussion Abstract only*

**[Challenges to promoting maternal respiratory syncytial virus vaccination in Japan](#)**

Emiko Oka, Yutaka Ueda, Asami Yagi, Masaki Machida, ... Takahiro Tabuchi

Article 126767

Article preview

*Discussion Abstract only*

**Closing the gap on vaccine uptake in developing countries: Is there a role for cash incentives?**

Ryoko Sato

Article 126763

*Review article Open access*

**Reverse vaccinology: A strategy also used for identifying potential vaccine antigens in poultry**

Noémie Gloanec, Muriel Guyard-Nicodème, Marianne Chemaly, Daniel Dory

Article 126756

*Research article Abstract only*

**Active vaccine safety surveillance in low- and middle-income countries: Challenges for vaccine manufacturers from emerging countries**

Patricia Mouta Nunes de Oliveira, Katharina Hartmann, Chetanraj Bhamare, Maria Beatriz Bastos Lucchesi, on behalf of the DCVMN PV Working Group

Article 126727

*Research article Abstract only*

**Association between adults' vaccine literacy and their intention to recommend older family members for influenza vaccine**

Zhiheng Liao, Lisha Deng, Jingwei Luo, Minjuan Shi, ... Caijun Sun

Article 126757

*Research article Abstract only*

**A decade of rotavirus vaccination in the World Health Organization African Region: An in-depth analysis of vaccine coverage from 2012 to 2023**

Jason M. Mwenda, Inácio Mandomando, Archibald Kwame Worwui, Marta Gacic-Dobo, ... Benido Impouma

Article 126768

**Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 22 Feb 2025]

*Open Access Article*

**Do We Have a Common Understanding of How Vaccine Policy Affects Health Equity? Evaluating Variability in the Advisory Committee on Immunization Practices' Equity Assessment**

by Kathleen Dooling, Elif Alyanak, Dial Hewlett, Haley Payne, Vincenza Snow, Mitchell Finkel, Maura Burns, Brett Hauber, Joshua Coulter and Ronika Alexander-Parrish

Vaccines 2025, 13(3), 214; <https://doi.org/10.3390/vaccines13030214> - 21 Feb 2025

*Abstract*

Background/Objectives: The Advisory Committee on Immunization Practices' (ACIP) Evidence to Recommendation (EtR) Framework has assessed vaccine equity, in addition to clinical and epidemiological data, since 2020. The domain's use has not yet been evaluated. Methods: Authors assessed web-published, Equity domain-inclusive ACIP Work Group [..

*Open Access Review*

**Molecular Farming for Immunization: Current Advances and Future Prospects in Plant-Produced Vaccines**

by Dang-Khoa Vo and Kieu The Loan Trinh



Vaccines 2025, 13(2), 191; <https://doi.org/10.3390/vaccines13020191> - 15 Feb 2025

#### *Abstract*

Using plants as bioreactors, molecular farming has emerged as a versatile and sustainable platform for producing recombinant vaccines, therapeutic proteins, industrial enzymes, and nutraceuticals. This innovative approach leverages the unique advantages of plants, including scalability, cost-effectiveness, and reduced risk of contamination with human [...]

#### **Value in Health**

February 2025 Volume 28 Issue 2 p175-322

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

#### **World Development**

Volume 186 February 2025

<https://www.sciencedirect.com/journal/world-development/vol/186/suppl/C>

[Reviewed earlier]

.....  
.....

#### ***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)

:: [\*WHO\*](#)

:: [\*Organization Announcements\*](#)

:: [\*Journal Watch\*](#)

:: [\*Pre-Print Servers\*](#)

.....  
.....

#### ***Pre-Print Servers***

##### **arxiv**

<https://arxiv.org/>

[Accessed 22 Feb 2025]

*[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]*

[arXiv:2502.09659](#) (cross-list from cs.CL) [pdf, other]

#### **[Cancer Vaccine Adjuvant Name Recognition from Biomedical Literature using Large Language Models](#)**

[Hasin Rehana](#), [Jie Zheng](#), [Leo Yeh](#), [Benu Bansal](#), [Nur Bengisu Çam](#), [Christianah Jemiyo](#), [Brett McGregor](#), [Arzucan Özgür](#), [Yongqun He](#), [Jungk Hur](#)

#### **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 22 Feb 2025]

[No new digest content identified]

**medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 22 Feb 2025]

[Filter: All articles]

**Immunogenicity of co-administered vaccine antigens with whole-cell or acellular pertussis vaccines in infancy: a randomised controlled trial**

Gladymar Perez Chacon, Sonia McAlister, James Totterdell, Marie J. Estcourt, Julie A. Marsh, Mark Jones, Kirsten P. Perrett, Dianne E. Campbell, Nicholas Wood, Michael Gold, Claire S. Waddington, Michael O'Sullivan, Nigel Curtis, Ushma Wadia, Peter B. McIntyre, Patrick G. Holt, Tom Snelling, Peter C. Richmond

medRxiv 2025.02.16.25321528; doi: <https://doi.org/10.1101/2025.02.16.25321528>

**Cost-effectiveness of routine COVID-19 adult vaccination programmes in England**

Matt J Keeling, Edward M Hill, Stavros Petrou, Phuong Bich Tran, May Ee Png, Sophie Staniszewska, Corinna Clark, Katie Hassel, Julia Stowe, Nick Andrews

medRxiv 2024.11.08.24316972; doi: <https://doi.org/10.1101/2024.11.08.24316972>

*Revision*

**Active vaccine safety surveillance: Experience from a prospective cohort event monitoring study of COVID-19 vaccines in Kenya**

Don B Odhiambo, Donald Akech, Boniface Karia, Makobu Kimani, Samuel Sang, Antipa Sigilai, Shirine Voller, Christine Mataza, David Mang'ong'o, Rose Jalang'o, Martha Mandale, Anthony O Etyang, J Anthony G Scott, Ambrose Agweyu, E Wangeci Kagucia

medRxiv 2025.02.18.25322051; doi: <https://doi.org/10.1101/2025.02.18.25322051>

**COVID-19 Vaccination Data Management and Visualization Systems for Improved Decision-Making: Lessons Learnt from Africa CDC Saving Lives and Livelihoods Program**

Raji Tajudeen, Mosoka Papa Fallah, John Ojo, Tamrat Shaweno, Wondwossen Amanuel, Michael Sileshi, Frehiwot Mulugeta, Moses Bamatura, Dennis Kibiye, Patrick Chanda Kabwe, Senga Sembuche, Ngashi Ngongo, Nebiyu Dereje, Jean Kaseya

medRxiv 2025.02.14.25322288; doi: <https://doi.org/10.1101/2025.02.14.25322288>

**Progress in Epidemic Ready Primary Health Care: Early Pilot Results from Four African Countries (Ethiopia, Nigeria, Sierra Leone and Uganda), December 2023-October 2024**

Stacey Mearns, Moreen Kamateeka, Tochi Okwor, Aisha Abba, Celestina Obiekea, Jenom Danjuma, Arone Mebrhatu Haile, Daniel Damtew, Damene Debalke, Joseph Sam Kanu, Ramatu Ngauja, Susan Michaels-Strasser, Abdullah Wailagala, Allan Muruta, Atim Dansan, Amy Elizabeth Barrera-Cancedda, Samantha Kozikott, Justine Landegger, Leena N Patel, Amanda McClelland

medRxiv 2025.02.14.25322294; doi: <https://doi.org/10.1101/2025.02.14.25322294>

MedRxiv 2025.02.19.25322432; doi: <https://doi.org/10.1101/2025.02.19.25322432>

**Towards Monitoring of Global Health Research: An Exploratory Analysis of Transparency and Stakeholder Engagement**

Samruddhi Yerunkar, Nicole Hildebrand, Daniel Strech

medRxiv 2024.12.30.24319762; doi: <https://doi.org/10.1101/2024.12.30.24319762> Revision

**A new approach to estimating HIV incidence and the size of the infected and undiagnosed population in high immigration settings**

Amber Kunkel, Françoise Cazein, Florence Lot, Julie Muzzolon, Nikos Pantazis, Amadou Alioum

medRxiv 2025.02.14.25322154; doi: <https://doi.org/10.1101/2025.02.14.25322154>

## **OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

*[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]*

*[No new digest content identified]*

## **Wellcome Open Research**

<https://wellcomeopenresearch.org/browse/articles>

*[Accessed 22 Feb 2025]*

*[No new digest content identified]*

\*

\*

\*

\*

## ***Think Tanks***

### **Brookings** [to 22 Feb 2025]

<http://www.brookings.edu/>

*Reports, Events*

*No new digest content identified.*

### **Center for Global Development** [to 22 Feb 2025]

<https://www.cgdev.org/>

*All Research*

*No new digest content identified.*

### **Chatham House** [to 22 Feb 2025]

<https://www.chathamhouse.org/>

*Selected Analysis, Comment, Events*

*No new digest content identified.*

### **Council on Foreign Relations** [to 22 Feb 2025]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*

*No new digest content identified.*

### **CSIS** [to 22 Feb 2025]

<https://www.csis.org/>

*Reports [Selected]*

*No new digest content identified.*

### **Kaiser Family Foundation** [to 22 Feb 2025]

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Newsroom*

*No new digest content identified.*

**McKinsey Global Institute** [to 22 Feb 2025]

<https://www.mckinsey.com/mgi/overview>

*Latest Research*

*No new digest content identified.*

**ODI [Overseas Development Institute]** [to 22 Feb 2025]

<https://odi.org/en/publications/>

*Publications [Selected]*

*No new digest content identified.*

**Pew Research Center** [to 22 Feb 2025]

<https://www.pewresearch.org/>

*Latest Publications [Selected]*

*No new digest content identified.*

**Rand** [to 22 Feb 2025]

<https://www.rand.org/pubs.html>

*Published Research [Selected]*

*Research Feb 21, 2025*

**[Demographic Variation In US Outpatient Hydroxychloroquine And Ivermectin Use During The COVID-19 Pandemic](#)**

Using insurance claims for 8.1 million patients from all fifty US states, we evaluated COVID-19-associated outpatient hydroxychloroquine and ivermectin use and spending throughout the public health emergency versus pre-public health emergency rates.

*Research Feb 20, 2025*

**[Health Equity Checklist for Research](#)**

The health equity checklist provides a practical guide for researchers, community partners, and participants to reflect on inclusivity, cultural relevance, and social justice in health research.

*Research Feb 20, 2025*

**[Steps Toward AI Governance: Insights and Recommendations from the 2024 EqualAI Summit](#)**

EqualAI's 2024 artificial intelligence (AI) summit facilitated dialogue on AI development, acquisition, and integration. These conference proceedings describe key summit insights about best practices, metrics, and tools for evaluating AI systems.

**Urban Institute** [to 22 Feb 2025]

<https://www.urban.org/publications>

**[New Research Publications - Selected](#)**

**World Economic Forum** [to 22 Feb 2025]

<https://agenda.weforum.org/press/>

*Media [Selected]*

*No new digest content identified.*

\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \*